Deutsche Bank AG Takes Position in Organogenesis $ORGO

Deutsche Bank AG purchased a new position in shares of Organogenesis (NASDAQ:ORGO) in the second quarter, HoldingsChannel reports. The firm purchased 1,706,186 shares of the company’s stock, valued at approximately $4,146,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. SG Americas Securities LLC lifted its position in Organogenesis by 39.8% in the first quarter. SG Americas Securities LLC now owns 790,766 shares of the company’s stock valued at $1,874,000 after buying an additional 225,265 shares during the last quarter. GSA Capital Partners LLP purchased a new position in Organogenesis during the fourth quarter worth about $992,000. Flax Pond Capital LLC acquired a new stake in shares of Organogenesis during the fourth quarter valued at about $2,197,000. Intrepid Family Office LLC raised its stake in shares of Organogenesis by 24.8% in the 4th quarter. Intrepid Family Office LLC now owns 100,000 shares of the company’s stock valued at $518,000 after acquiring an additional 19,900 shares during the period. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in shares of Organogenesis in the 4th quarter valued at approximately $91,000. 49.57% of the stock is owned by institutional investors and hedge funds.

Organogenesis Trading Up 4.2%

NASDAQ ORGO opened at $1.74 on Wednesday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.00 and a current ratio of 3.52. The firm has a market cap of $223.90 million, a price-to-earnings ratio of -2.02 and a beta of 1.34. The firm has a 50 day simple moving average of $2.28 and a 200-day simple moving average of $2.57. Organogenesis has a one year low of $1.54 and a one year high of $7.08.

Organogenesis (NASDAQ:ORGO) last announced its earnings results on Thursday, August 6th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.36). Organogenesis had a negative return on equity of 23.89% and a negative net margin of 19.94%.The business had revenue of $43.76 million for the quarter, compared to analysts’ expectations of $54.27 million.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ORGO. UBS Group set a $3.00 price objective on shares of Organogenesis in a report on Thursday, May 28th. Truist Financial dropped their target price on shares of Organogenesis from $3.00 to $2.00 and set a “hold” rating for the company in a report on Friday, August 7th. BTIG Research lowered Organogenesis from a “buy” rating to a “neutral” rating in a research report on Friday, May 8th. Weiss Ratings cut Organogenesis from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday. Finally, Wall Street Zen cut Organogenesis from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus price target of $4.33.

About Organogenesis

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.